MedTrace Logo

Glucose Variability in Subclinical Hypertrophy

NCT02748434 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-05-01

No results posted yet for this study

Summary

Evaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy through short-term continuous glucose monitoring has shown inconsistent results and it is yet unknown how or if subclinical lipohypertrophy affects absorption. In this study investigators propose to enroll at least 20 people who participated in phase 1 and who were determined to have subclinical lipohypertrophy to examine the correlation between glycemic control and amount of insulin injected in subclinical hypertrophic areas using capillary blood glucose and continuous glucose monitoring.

Conditions

Interventions

OTHER

Lipohypertrophy

OTHER

Normal Subcutaneous Tissue

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Graydon Meneilly, MD · University of British Columbia

  • Jordanna Kapeluto, MD · University of British Columbia

  • Breay Paty, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2025-06-30
Completion
2025-09-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02748434 on ClinicalTrials.gov